{"id":41903,"date":"2025-12-17T20:00:00","date_gmt":"2025-12-17T13:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=41903"},"modified":"2025-12-17T20:00:00","modified_gmt":"2025-12-17T13:00:00","slug":"medigene-announces-catalyze-agreement-with-lilly-to-advance-next-generation-obesity-therapeutics","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=41903","title":{"rendered":"MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics"},"content":{"rendered":"

SEOUL, South Korea<\/span><\/span>, Dec. 17, 2025<\/span><\/span> \/PRNewswire\/ — MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today\u00a0that it has entered into a Catalyze agreement with Eli\u00a0Lilly\u00a0and Company (Lilly) to\u00a0advance a\u00a0next-generation\u00a0therapeutic\u00a0for obesity.\u00a0<\/p>\n

\n

\"MEDI&GENE <\/a>
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics<\/span><\/p>\n<\/div>\n

MEDI&GENE’s discovery platform\u00a0is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects.<\/p>\n

Under\u00a0the\u00a0agreement,\u00a0Lilly ExploR&D will bring Lilly’s expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.<\/p>\n

“We are excited to work with Lilly to advance a next-generation obesity drug candidate. We believe this collaboration will accelerate clinical development and help bring differentiated solutions to patients with obesity,” said Min-Jeong Shin<\/span>, CEO of MEDI&GENE.<\/p>\n

Founded in 2021, MEDI&GENE has established a discovery engine centered on metabolic and obesity-related pathways and has identified multiple innovative candidates through its mechanistic platform. The company expects that the collaboration will support the continued advancement of its research initiatives in next-generation obesity therapeutics.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SEOUL, South Korea<\/span><\/span>, Dec. 17, 2025<\/span><\/span> \/PRNewswire\/ — MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today\u00a0that it has entered into a Catalyze agreement with Eli\u00a0Lilly\u00a0and Company (Lilly) to\u00a0advance a\u00a0next-generation\u00a0therapeutic\u00a0for obesity.\u00a0<\/p>\n

\n

\"MEDI&GENE <\/a>
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics<\/span><\/p>\n<\/div>\n

MEDI&GENE’s discovery platform\u00a0is designed to unlock novel therapeutic pathways that have the potential to sustain long-term weight maintenance, lean mass maintenance, and durability of desired metabolic effects.<\/p>\n

Under\u00a0the\u00a0agreement,\u00a0Lilly ExploR&D will bring Lilly’s expertise in molecule engineering and development to a MEDI&GENE asset, with the goal to advance the program to clinical trial readiness. Lilly ExploR&D is part of the Lilly Catalyze360 suite of offerings designed to empower biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.<\/p>\n

“We are excited to work with Lilly to advance a next-generation obesity drug candidate. We believe this collaboration will accelerate clinical development and help bring differentiated solutions to patients with obesity,” said Min-Jeong Shin<\/span>, CEO of MEDI&GENE.<\/p>\n

Founded in 2021, MEDI&GENE has established a discovery engine centered on metabolic and obesity-related pathways and has identified multiple innovative candidates through its mechanistic platform. The company expects that the collaboration will support the continued advancement of its research initiatives in next-generation obesity therapeutics.<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[1],"tags":[],"class_list":["post-41903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41903"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/41903\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}